The treatment of ulcerative colitis has improved since the appearance of Tumor Necrosis Factor (TNF)-alpha inhibitors. However, the use of TNF-alpha inhibitors increases the risk of opportunistic infections. We describe two cases of Pneumocystis jiroveci pneumonia during infliximab therapy for active ulcerative colitis. They were successfully treated with sulfametoxazole/trimetroprim. High awareness of P. jiroveci pneumonia in patients who develop pulmonary symptoms with hypoxia during TNF-alpha modulator therapy is recommended.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
jiroveci pneumonia
12
pneumonia infliximab
8
ulcerative colitis
8
tnf-alpha inhibitors
8
[pneumocystis jiroveci
4
infliximab therapy]
4
therapy] treatment
4
treatment ulcerative
4
colitis improved
4
improved appearance
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!